Important to know: Ruconest has orphan designation by FDA and an SPA. Perhaps we get a priority review and the drug is approved within 6 months from filing the NDA. This could be - IMHO - April 2013 (if filed in November).
SNTS estimates the revenue potential to 200 mio usd, so the value of approved Ruconest for SNTS should 200mio usd / 62 mio shares = 3 usd per share x 3 (revenue multiple) = 9 usd. Thats a double from todays share price and will be gradually realised in the future.